Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 15

Cat.No. Product Name Information/Activity
BCC5818 Threo-methylphenidate hydrochloride 298-59-9
BCC7226 Nomifensine Nomifensine maleate is a selective inhibitor of dopamine uptake, used in adult attention deficit disorder.
BCN4960 Reserpine Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
BCC7090 Rimcazole dihydrochloride 75859-03-9
BCC5277 Tetrabenazine Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.
BCC2061 XMD17-109 XMD17-109 is a novel, specific ERK-5 inhibitor, with an IC50 of 162 nM.
BCC3669 FR 180204 FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively.
BCC2051 VX-11e VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.
BCC7745 TMCB 905105-89-7
BCC2062 XMD8-92 XMD8-92 is a highly selective ERK5/BMK1 inhibitor with dissociation constant (Kd) value of 80 nM.